Would love to see LL CD12 outcomes based on when it was given relative to symptom onset and when other treatments were given, and also to understand why 72 subjects got no other treatment at all. Did those 72 show up at the hospital already very sick and had comorbidities precluding other treatments? Seems hard to tease out who LL will help, but it's good to see that they keep looking at the trial data. Makes sense to keep giving doses q. week.